TY - JOUR AU - Sheta, Razan AU - Bachvarova, Magdalena AU - Plante, Marie AU - Renaud, Marie-Claude AU - Sebastianelli, Alexandra AU - Gregoire, Jean AU - Navarro, Jamilet Miranda AU - Perez, Ricardo Bringas AU - Masson, Jean-Yves AU - Bachvarov, Dimcho PY - 2020 DA - 2020/11/19 TI - Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy JO - Journal of Translational Medicine SP - 439 VL - 18 IS - 1 AB - Poly(ADP-ribose) polymerase inhibitors (PARPis) specifically target homologous recombination deficiency (HRD) cells and display good therapeutic effect in women with advanced-stage BRCA1/2-mutated breast and epithelial ovarian cancer (EOC). However, about 50% of high grade serous ovarian cancers (HGSOC) present with HRD due to epigenetic BRCA1 inactivation, as well as genetic/epigenetic inactivation(s) of other HR genes, a feature known as “BRCAness”. Therefore, there is a potential for extending the use of PARPis to these patients if HR status can be identified. SN - 1479-5876 UR - https://doi.org/10.1186/s12967-020-02613-4 DO - 10.1186/s12967-020-02613-4 ID - Sheta2020 ER -